Recursion Historical Balance Sheet
| RXRX Stock | USD 5.89 0.11 1.83% |
Trend analysis of Recursion Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 255.6 M, Other Liab of 84.8 M, Net Tangible Assets of 584.1 M or Property Plant And Equipment Net of 78.5 M provides information on Recursion Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Recursion Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Recursion Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Recursion Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Recursion Pharmaceuticals is a good buy for the upcoming year.
Recursion Pharmaceuticals Inventory |
|
Recursion |
About Recursion Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Recursion Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Recursion Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Recursion Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Recursion currently owns. An asset can also be divided into two categories, current and non-current.
Recursion Pharmaceuticals Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Recursion Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Recursion Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Recursion Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Recursion Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Recursion Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Recursion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.At this time, Recursion Pharmaceuticals' Property Plant Equipment is fairly stable compared to the past year. Intangible Assets is likely to rise to about 38.3 M in 2024, whereas Total Assets are likely to drop slightly above 520.4 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 11.5M | 51.0M | 50.7M | 31.9M | Total Assets | 610.3M | 701.3M | 653.7M | 520.4M |
Recursion Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Recursion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.